Corvus Pharmaceuticals (FRA:C17) Current Accrued Expense : €2.64 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Current Accrued Expense?

Corvus Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2025 was €2.64 Mil.

Corvus Pharmaceuticals's quarterly Current Accrued Expense declined from Sep. 2024 (€2.89 Mil) to Dec. 2024 (€2.50 Mil) but then increased from Dec. 2024 (€2.50 Mil) to Mar. 2025 (€2.64 Mil).

Corvus Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2022 (€5.93 Mil) to Dec. 2023 (€2.79 Mil) and declined from Dec. 2023 (€2.79 Mil) to Dec. 2024 (€2.50 Mil).

Corvus Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Corvus Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Current Accrued Expense Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

4.27

4.53

5.93

2.79

2.50

Corvus Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															3.04	3.15	2.89	2.50	2.64

Corvus Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Corvus Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (FRA:C17) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

CRVS:USA

Address

901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals Headlines

No Headlines